Back | Next |
home / stock / lgvn / lgvn message board
Subject | By | Source | When |
---|---|---|---|
Common most of pos stocks doubled 1 more | Roadtojourney | investorshub | 05/16/2022 4:12:33 PM |
Been watching this move all around on tiny | pinkslipjunkie | investorshub | 04/12/2022 3:44:39 PM |
Looking for a pullback. around 6 | timetomakemoney | investorshub | 04/06/2022 7:15:53 PM |
Keep It Low And Wait For The Breakout! | dennisv | investorshub | 04/06/2022 4:30:46 PM |
Agree, $CLOV did the same thing destroyed | timetomakemoney | investorshub | 04/06/2022 12:34:57 PM |
so many holes to leak from | TheFinalCD | investorshub | 04/06/2022 3:23:53 AM |
There it goes, another one bites the dust. | dinogreeves | investorshub | 04/06/2022 12:15:21 AM |
Or the news was leaked?? Todays action should | Roadtojourney | investorshub | 04/05/2022 8:40:06 PM |
makes me think the people involved with the | TheFinalCD | investorshub | 04/05/2022 8:37:20 PM |
$50M Offering https://ih.advfn.com/stock-market/NASDAQ/longeveron-$LGVN/st | TheFinalCD | investorshub | 04/05/2022 8:34:45 PM |
check the S-3 Filing | TheFinalCD | investorshub | 04/05/2022 8:32:55 PM |
And back to where it was, seems like | Roadtojourney | investorshub | 04/05/2022 6:25:47 PM |
CONGRAT$ | TheFinalCD | investorshub | 04/05/2022 4:58:37 PM |
Is Attached! | dennisv | investorshub | 04/05/2022 4:16:09 PM |
We Are Back In Town! | dennisv | investorshub | 04/05/2022 4:00:28 PM |
Breakthrough! | dennisv | investorshub | 04/05/2022 3:48:26 PM |
A Lot Of Interest! | dennisv | investorshub | 04/05/2022 2:57:44 PM |
Just Carry On! | dennisv | investorshub | 04/05/2022 2:17:32 PM |
I made $1,100 of the play | Pedro2004 | investorshub | 04/05/2022 2:17:12 PM |
Recovery Day!!! | dennisv | investorshub | 04/05/2022 1:55:32 PM |
News, Short Squeeze, Breakout and More Instantly...
Longeveron Inc. Company Name:
LGVN Stock Symbol:
NASDAQ Market:
Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of bu...
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board...